Clinical trials: Acute Gouty Arthritis
Gout Arthritis
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
- Trial name
- NCT07708181
- Testing
- SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W
- Volunteers
- 200 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom…
- Trial name
- β-RELIEVED (NCT01029652)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 47 sites in Australia, Belgium and 15 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Acute Gout Flare
Study Utilizing Rilonacept in Gout Exacerbations
This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days.
- Trial name
- SURGE (NCT00855920)
- Testing
- Rilonacept, Indomethacin
- Where
- 44 sites in United States
- Volunteers
- 225 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Gouty Arthritis
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout.
- Trial name
- NCT00170781
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 234 people
- Sponsor
- Novartis
Acute Gout Arthritis
Safety & Efffficacy of Genakumab in Patients With Frequent Flares
The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).
- Trial name
- NCT05983445
- Testing
- genakumab, Diprospan
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Gout
Allopurinol in Acute Gout
The objectives of the present study are to determine if starting treatement of hyperuricemia with allopurinol during an acute gout crises has an impact on the duration or the severity of the crises
- Trial name
- NCT01775098
- Testing
- allopurinol
- Sponsor
- Université de Sherbrooke
Gout Attack
Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to triamcinolone acetonide an FDA approved drug to treat…
- Trial name
- NCT03636373
- Testing
- Etanercept, Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rutgers, The State University of New Jersey
Acute Gouty Arthritis
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult…
- Trial name
- NCT01593527
- Testing
- ACZ885, Triamcinelone acetonide
- Sponsor
- Novartis Pharmaceuticals
Gout
A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating…
- Trial name
- NCT00819585
- Testing
- Canakinumab, Colchicine, Allopurinol
- Where
- 89 sites in United States, Argentina and 16 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Infection, Heart Failure
Serum Potassium Prediction Using Machine Learning and Single-lead ECG
This is a retrospective study drawing on data from the Brigham and Women's Hospital Home Hospital Program's Database. Sociodemographic and clinical data from a training cohort were used to train a machine learning algorithm to…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT07493798
- Testing
- Potassium estimation algorithm
- Where
- 2 sites in United States
- Sponsor
- Brigham and Women's Hospital
Gout Flare
Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare
Gout, secondary to sodium urate crystal deposition, is responsible of recurrent inflammatory painful flares. Efficacy of colchicine which is the first line drug for the treatment and prophylaxis of gout flare varies and only half…
- Trial name
- COMpARE (NCT03933007)
- Testing
- Colchicine,, midazolam,, fexofenadine
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gouty Arthritis
Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective
The purpose of this pivotal Phase III study is to support the registration of canakinumab for the indication of gout in China, a replicate of global studies CACZ885H2356 \& CACZ885H2357 by demonstrating in patients with frequent…
- Trial name
- NCT01362608
- Testing
- Canakinumab, ACZ885, Triamcinolone acetonide
- Where
- 20 sites in Argentina, China and 2 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Acute Kidney Injury, Sepsis
Novel Biomarkers for Early Renal Injury in Children With Sepsis
Toxicosis often leads to multiple organ failure (MODS), with the kidney being the primary target organ due to its sensitivity to infection and ischemia.
- Conditions
- Acute Kidney Injury, Sepsis, Gout Flare
- Trial name
- NCT06197828
- Testing
- This study is an observational studie which have no intervention
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Infections, Heart Failure
Rural Hospital-Level Care at Home for Acutely Ill Adults
This study examines the implications of providing hospital-level care in rural homes.
- Conditions
- Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT05256303
- Testing
- Home Hospital care, Traditional Hospital care
- Where
- 3 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
Acute Gouty Arthritis
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
This is a multi center,randomized,double-blind,double-dummy,active-controlled study,and planned enrollment of 120-170 subjects,an interim analysis will be conducted after first 60 subjects complete the 72 -hour pain Visual…
- Trial name
- NCT07453004
- Testing
- Plonmarlimab, Compound betamethasone
- Where
- 30 sites in China
- Volunteers
- 170 people
- Sponsor
- TJ Biopharma Co., Ltd.
Pharmacokinetics
Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study
This study will characterize the pharmacokinetics of colchicine after an oral dosing regimen of 4.8 mg over 6 hours. In addition it will compare the electrocardiogram (ECG) changes, if any, from this dosing regimen to that of a…
- Trial name
- NCT01018420
- Testing
- Colchicine, Moxifloxacin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Gout Flare
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy
The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.
- Trial name
- NCT04069325
- Testing
- simiaowan, febuxostat
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Acute Gout
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine.
- Trial name
- NCT00798369
- Testing
- Canakinumab, Triamcinolone acetonide
- Where
- 75 sites in United States, Argentina and 9 more
- Volunteers
- 200 people
- Sponsor
- Novartis
Gout, Gout Acute
Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout
Medical teaching suggests allopurinol should not be initiated in the setting of an acute attack of gout, as rapid lowering of serum urate may exacerbate the attack.
- Trial name
- NCT01310673
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- White River Junction Veterans Affairs Medical Center
Gout, Chronic Kidney Diseases
Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study
The aim of this study is to determine the feasibility of running a phase III double-blind, double-dummy randomised controlled trial comparing Depo-Medrone 120mg intramuscular injection vs.
- Trial name
- ASGARD (NCT02578394)
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Mid and South Essex NHS Foundation Trust